ArticleClinical orthopaedics and related research2009
Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database.
Article in Clinical orthopaedics and related research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Published Cases of Primary Epithelioid Sarcoma of the Spine.Medical science monitor : international medical journal of experimental and clinical research · 2023Pooled it
- Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.European journal of cancer (Oxford, England : 1990) · 2019Trial
- Epithelioid Sarcoma: A Review and Update.Cancers · 2026Review
- Epithelioid Sarcoma of the Oral Cavity: A Multi-institutional Clinicopathologic and Immunophenotypic Characterization of Five Cases and Comprehensive Literature Review.Head and neck pathology · 2026Review
- Prognostic determinants and survival outcomes in epithelioid sarcoma: A contemporary population-based analysis of 1123 patients.Medicine · 2026Article
- Precision epigenetic therapies in oncology.Cancer metastasis reviews · 2025Review
- AURKA/PLK1/CDC25C Axis as a Novel Therapeutic Target in INI1-Deficient Epithelioid Sarcoma.Cancer science · 2025Article
- Epithelioid sarcoma of the pretragus: a rare pediatric entity with an unusual site.Journal of surgical case reports · 2024Article
- The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma.BMC cancer · 2024Article
- Uncommon Thigh Mass in Neurofibromatosis Type 1: Unveiling Aggressive Epithelioid Sarcoma.European journal of case reports in internal medicine · 2024Article
- Epithelioid Sarcoma of the Spine: A Review of Literature and Case Report.Journal of clinical medicine · 2023Article
- Proximal-type epithelioid sarcoma of the perineum: A case report and literature review.Frontiers in oncology · 2023Article
- Epithelioid sarcoma and its outcome: a retrospective analysis from a tertiary care center in North India.Future science OA · 2022Article
- Review
- Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology.Clinical and translational medicine · 2022Article
- Epithelioid Sarcoma of the External Auditory Canal: An Uncommon Tumor at an Unusual Site and a Brief Overview of the Literature.Head and neck pathology · 2021Review
- Primary Epithelioid Sarcoma Manifesting as a Fungating Scalp Mass - Imaging Features and Treatment Options. A Case Report and Literature Review.Journal of radiology case reports · 2021Review
- The evolving management of epithelioid sarcoma.European journal of cancer care · 2021Article
- A case of primary distal-type epithelioid sarcoma of the lumbar vertebra with a review of literature.Virchows Archiv : an international journal of pathology · 2021Review
- Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledCurrent stratification of prognosis in patients with epithelioid sarcoma (ES) is based largely on data reported by individual centers with a limited number of patients. We sought to identify the important prognostic parameters using the Surveillance, Epidemiology, and End Results (SEER) database. We identified 441 patients with ES in the database and extracted information regarding patient demographics and clinical characteristics. Kaplan-Meier, log-rank, and Cox regression were used for analysis. Disease-specific survival declined until 100 months after diagnosis after which survival was unrelated to epithelioid sarcoma. The overall incidence of ES during 2005 was 0.041 per 100,000. The reported incidence has increased since 1973, with an annual percentage change of 5.217%. On multivariate analysis, only age younger than 16 years, local stage of disease, or negative nodes and surgical resection of the tumor predicted better disease-specific survival. We observed no increase in survival by comparing decades of diagnosis since 1986. The SEER database shows only age younger than 16 years, negative nodes, or local stage of disease and operability of primary disease independently predict survival in patients with ES. LEVEL OF EVIDENCE: Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.